Filipa Englefield’s Post

🔬 𝗡𝗲𝘄 𝗧𝟭 𝗮𝗻𝗱 𝗧𝟮 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗜𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 🔬 𝗥𝗲𝘃𝗲𝗮𝗹 𝘆𝗼𝘂𝗿 𝗱𝗿𝘂𝗴’𝘀 𝗮𝗻𝘁𝗶-𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝘄𝗶𝘁𝗵 𝗮 𝗵𝘂𝗺𝗮𝗻 𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹𝗹𝘆 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗧𝘆𝗽𝗲 𝟭 𝗮𝗻𝗱 𝗧𝘆𝗽𝗲 𝟮 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀-𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗱 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 𝗮𝘀𝘀𝗮𝘆! Using Endoc-BH5® cells, our latest innovative assay 𝗿𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝗲𝘀 𝗶𝗻 𝘃𝗶𝘁𝗿𝗼 𝘁𝗵𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝗼𝗯𝘀𝗲𝗿𝘃𝗲𝗱 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗼𝗳 𝗵𝘂𝗺𝗮𝗻 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗯𝗲𝘁𝗮 𝗰𝗲𝗹𝗹𝘀 𝘁𝗼 𝗰𝘆𝘁𝗼𝗸𝗶𝗻𝗲-𝗶𝗻𝗱𝘂𝗰𝗲𝗱 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 observed in Type 1 and Type 2 diabetes. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗮𝘀𝘀𝗮𝘆: https://lnkd.in/ebTxcKke 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀: [email protected] #Assay #DiabetesResearch #Type1Diabetes #Type2Diabetes #EndoCBH5 #BetaCell #Pancreas # #CellModel #InVitro #Research #Diabetes #ResearchModel #Research #TranslationalResearch #Innovation #Biotechnology #DrugDevelopment #Technology #MedicalResearch #Biomedical #Bioengineering #Science #HumanCellDesign

Nature's wisdom: The profound impact of indigenous knowledge on modern medicine As we celebrate Indigenous Peoples' Day, let's recognize the immense contribution of traditional knowledge to modern biotechnology and drug discovery. Did you know that around 40% of pharmaceutical products today draw from nature and traditional knowledge? [1] This includes landmark drugs like: • Artemisinin for malaria, from Chinese medicine • Triptolide and celastrol, promising anti-inflammatory and anti-cancer agents • Capsaicin for pain relief, from chili peppers [2] • Myricetin, showing GLP-1 agonist properties for potential diabetes treatment [4] However, this process raises important questions about intellectual property rights and benefit-sharing. As noted in a study, "When new plant-derived therapeutics based on indigenous knowledge are explored, it's important that pharmaceutical companies return benefits to the native populations and local governments." [3] It is indeed critical to ensure that if modern medicine owes to indigenous wisdom, indigenous communities are fairly compensated and credited for their contributions. Traditional medicines can impact modern drug discovery in unexpected ways. How can we better honor and integrate this ancestral knowledge while driving innovation forward? References: [1] World Health Organization. (2023). https://lnkd.in/egA5qx2j [2] Corson, T. W., & Crews, C. M. (2007). Cell, 130(5), 769-774. https://lnkd.in/eNm65rUy [3] Soejarto, D. D., et al. (1997). Journal of Ethnopharmacology, 51(1-3), 1-10. https://lnkd.in/ef3cFG-B [4] Li Y, et al. (2017). FASEB J. 31(6):2603-2611. https://lnkd.in/e5B4AMYH #IndigenousPeoplesDay #Biotechnology #DrugDiscovery #TraditionalMedicine #Innovation Illustration EMxMJ

Exciting research by George Biggs et al. developing a high-throughput, label-free quantification platform to profile cysteine-reactive fragments against the native proteome. Using timsTOF Pro 2, they achieved unprecedented cysteinome coverage, identifying approximately 23,000 cysteine sites per run (32K overall!). They screened 80 reactive fragments, uncovering over 400 ligand-protein interactions. This study is not just about numbers; it's about the potential to accelerate the discovery of new drugs and understand protein functions deeply. Exciting to see how characterizing peptides based on multiple properties (i.e., ion mobility, retention time, mass-to-charge ratio of precursor and fragments, and intensity) employing DIA with parallel accumulation-serial fragmentation (PASEF) can increase confidence and speed up ligand discovery. 🚀 #StayCurious! #Proteomics #MassSpectrometry #DrugDiscovery #Innovation #ScienceResearch #ChemoProteomics https://lnkd.in/g7nf654z

N-Glycosylation plays a critical role in the efficacy, safety, and pharmacokinetics of therapeutic antibodies. Predicting glycan patterns based on culture media markers allows for better control over this essential quality attribute. Dr Ian Walsh, Dr Ying Swan Ho and colleagues from #BTI explored how cell culture media markers influence N-glycosylation in monoclonal antibodies produced by Chinese Hamster Ovary cells. The researchers utilised machine learning (ML) models to predict N-glycan abundances, focusing on key glycan modifications such as fucosylation, galactosylation, mannosylation, and sialylation. They analysed bioreactor cultures under 12 different growth conditions, measuring parameters like dissolved oxygen, pH, and temperature. By quantifying spent media and calculating "media markers" (pseudo cell consumption rates from mass spectrometry peaks), they identified 18 key markers that could predict N-glycan patterns with: - 0.80 to 0.92 correlation for regression tasks - 75% to 97% area under curve (AUC) scores for classification tasks This approach shows that media composition is a powerful predictor of glycan quality, opening up possibilities for real-time glycosylation control in biomanufacturing. Find out more about this research at: https://lnkd.in/ehMxPgis Come work with us: https://lnkd.in/gRU66bP #ASTAR #CreatingGrowth #EnhancingLives #Biomanufacturing #Glycosylation #MonoclonalAntibodies #mAbs #MachineLearning

We are thrilled to introduce “Liquid-liquid phase separation in cells” – a Dewpoint-sponsored 𝘕𝘢𝘵𝘶𝘳𝘦 𝘊𝘰𝘭𝘭𝘦𝘤𝘵𝘪𝘰𝘯, which compiles prominent papers in the field of biomolecular #condensate science. The collection of articles, independently selected by the editorial staff at Nature Portfolio, includes reviews and original research articles that discuss: 🔬 The role of biomolecular condensates as hubs for splicing regulation and protein aggregation 🗺 Mapping the composition of endogenous biomolecular condensates  ⚙ Molecular mechanisms by which cancer-driving proteins restructure chromatin to promote uncontrolled cell proliferation For a limited time, the publications included in the editorial collection are freely accessible to all. https://lnkd.in/gv6crsZD  

Sharing interesting study from scientists at AstraZeneca. https://lnkd.in/gFaXVRBj In this article they describe the effects of droplet-based and microfluidic chip-based cell sorting on cellular metabolism and signaling. They found that droplet-based sorting caused greater changes, including elevated oxidative stress and suppression of mitochondrial metabolism, compared to microfluidic chip-based sorting. To gain a more mechanistic understanding of this observation, they employed stable isotope tracing and observed that microfluidic chip-based sorted cells recovered their metabolism and signaling state faster than droplet-based sorted cells. These authors suggest that microfluidic chip-based cell sorting may better preserve native cellular metabolism and enhance downstream studies, especially those involving signaling and metabolism. #flowcytometry #astrazeneca #metabolomics

𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐩𝐚𝐫𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: June and July Are you interested in keeping up with the latest publications from the Department? We have compiled all the publications released in June and July for your reading pleasure. You can find an RSS feed of our publications here: https://lnkd.in/eD2nmgjJ Dissecting the roles of dynamin and clathrin in platelet pinocytosis - Harper Group- https://lnkd.in/e56g2EUC Intestinal barrier function in the naked mole-rat: an emergent model for gastrointestinal insights - St John Smith Group - https://lnkd.in/eaZVGd8t α-Synuclein Oligomers Displace Monomeric α-Synuclein from Lipid Membranes - Kumita Group - https://lnkd.in/eRN2zZiA Can Current Molecular Docking Methods Accurately Predict RNA Inhibitors? - Rahman Group - https://lnkd.in/e5RRENuB #Publications #Research #Pharmacology #Cambridge

Biomarkers Market | Growing at CAGR 10.2% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 👉https://lnkd.in/eg8rG-Gp The size of global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. Companies From the Market Target ALS Biofourmis Exosome Diagnostics  Biological Dynamics BostonGene Ultivue MESO SCALE DIAGNOSTICS, LLC.   ABL Inc. Alto Neuroscience Cardio Diagnostics Holdings Inc.  Altoida, Inc. FLUIDDA Nucleai Geneoscopy Mitsubishi Tanabe Pharma America      AiCure Evvy Paige Amador Bioscience BioSensics #Biomarkers #Healthcare #Research #Medicine #Innovation #Science #Biotechnology #PrecisionMedicine #Diagnostics #BiomarkerDiscovery #HealthTech #MedicalResearch #PersonalizedMedicine #BiomarkerTesting #ClinicalTrials #Bioinformatics #HealthScience #BiomarkerDevelopment #PrecisionHealth #MedicalInnovation

Targeted protein #degradation: from mechanisms to #clinic. New molecular mechanisms can rapidly be translated - we can surely learn so much from nature. Great to be able to share this piece with Jonathan Tsai Ben Ebert and Eric Fischer. #TPD https://lnkd.in/gtrA7827

#Biobanking Market size is estimated to record more than USD 127 billion by 2032. The growing number of biobanking initiatives to assist researchers in recognizing the importance of pooling resources for accelerating scientific discovery will drive the industry gains.